Apraglutide is a Synthetic Peptide owned by VectivBio, and is involved in 10 clinical trials, of which 5 were completed, 4 are ongoing, and 1 is planned.

Apraglutide (FE-203799) acts as GLP-2 receptor agonist. The drug candidate elicits therapeutic intervention by activating GLP-2 receptor via activation of adenylate cyclase, and consequently restores the normal physiological function of GI tract affected by mucositis exhibiting intestine-trophic and intestine-protective activity.

The revenue for Apraglutide is expected to reach a total of $4.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Apraglutide NPV Report.

Apraglutide was originated by Ferring International Center and is currently owned by VectivBio.

Apraglutide Overview

Apraglutide (FE-203799) is under development for the treatment of short bowel syndrome intestinal failure (SBS-IF) and gastrointestinal acute graft versus host disease (GVHD). It is administered through subcutaneous route as a powder and solution for solution for injection. The drug candidate is a long acting synthetic peptide analogue of glucagon-like-peptide-2 (GLP-2) which acts on GLP-2 receptor. It is developed by using peptide technology. It was under development for the treatment of chemotherapy-induced gastro-intestinal mucositis.

VectivBio Overview

VectivBio is biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for for severe rare conditions with high unmet medical need. The company’s lead product candidate GLP-2, targeting short bowel syndrome. VectivBio is headquartered in Basel, Switzerland.

The operating loss of the company was US$86.7 million in FY2021, compared to an operating loss of US$57.3 million in FY2020. The net loss of the company was US$87 million in FY2021, compared to a net loss of US$59.9 million in FY2020.

Quick View – Apraglutide

Report Segments
  • Innovator
Drug Name
  • Apraglutide
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Immunology
  • Toxicology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.